


Stabilis



Cisplatin



Tradename

Abiplatin	Republic of South Africa
Accocit	Mexico
Briplatin	Japan
Cisplatex	Brazil
Cisplatine	France
Cisplatyl	France, Greece, Turkey
Citoplatino	Italy
Neoplatin	Spain
Pamifect	India
Placis	Spain, Turkey
Platamine	Greece, Italy, Morocco, Tunisia
Platidiam	Hungary, Poland
Platinex	Germany, Great Britain, Italy
Platinol	Austria, Belgium, Denmark, Finland, Greece, Luxembourg, Mexico, Netherlands, Sweden, Switzerland, United States of America
Platistil	Spain
Platistine	Belgium, Brazil, Luxembourg
Platosin	Belgium, Egypt, Greece, Japan, Netherlands, Romania, Turkey, Venezuela
Pronto Platamine	Italy
Tecnoplatine	Mexico



Stability in solutions

		0,166 mg/ml	30°C		14			147
PVC		0,6 mg/ml	20°C-24°C		9			164
PVC		0,1 mg/ml	25°C		28			3183
PVC		0,166 mg/ml	30°C		14			147
PVC		0,4 mg/ml	25°C		28			3183
PVC		1 mg/ml	25°C		14			855
PVC		1 mg/ml	37°C		14			855

PP	▲	0,166 mg/ml	30°C		14	◐		147
PE	▲	0,166 mg/ml	30°C		14	◐		147
POF	▲	0,006 mg/ml	25°C		21	◐		4137
POF	▲	0,06 mg/ml	25°C		21	◐		4137
POF	▲	0,12 mg/ml	25°C		21	◐		4137
POF	▲	0.5 mg/ml	2-8°C		28	◐		3670
EVA	▲	0,5 & 0,9 mg/ml	22°C		28	◐		149
EVA	▲	0,5 & 0,9 mg/ml	35°C		28	◐		149
?	▲	0,1 mg/ml	2-8°C		7	◐		1729
?	▲	0,1 mg/ml	21-25°C		4	◐		1729



Stability of mixtures

	▲	0,2 mg/ml	20,5°C-24°C		Etoposide : 0,2 & 0,4 mg/ml	48	✓	417
	▲	0,5 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4	✓	57
	▲	0,25 mg/ml	?	?	Palonosetron hydrochloride : 25 µg/ml	4	✓	1950
PVC	▲	0,455 mg/ml	2-8°C		Ondansetron hydrochloride : 1,091 mg/ml	24	✓	53
PVC	▲	0,2 mg/ml	20,5°C-24°C		Etoposide : 0,2 & 0,4 mg/ml	48	✓	417
PVC	▲	0,1 mg/ml	25°C		Potassium chloride : 2,9 mEq/l Magnesium sulfate : 1,9 mg/ml	28	◐	3183
PVC	▲	0,455 mg/ml	30°C		Ondansetron hydrochloride : 1,091 mg/ml	168	✓	53
PVC	◆	0,05 & 0,2 mg/ml	-15°C		Magnesium sulfate : 1 & 2 mg/ml Mannitol : 18,75 mg/ml	30	◐	1080
PVC	◆	0,05 & 0,2 mg/ml	25°C	?	Magnesium sulfate : 1 & 2 mg/ml Mannitol : 18,75 mg/ml	48	✓	1080
PVC	◆	0,05 & 0,2 mg/ml	4°C		Mannitol : 18,75 mg/ml Magnesium sulfate : 1 & 2 mg/ml	4	◐	1080
○	▲	0,2 mg/ml	2-8°C		Ondansetron hydrochloride : 0,48 mg/ml	168	✓	53
○	▲	0,2 mg/ml	30°C		Ondansetron hydrochloride : 0,48 mg/ml	24	✓	53
?	▲◆	0,084 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4	✓	1026








Factors which affect stability

				410
				3578
				301
				3578
				1729
	4°C > 0,5 mg / n			164
	4°C > 0,6 mg / n			742
				410
	< 0,3%			409



Incompatibilities

Cisplatin : 1 mg/ml Amifostine : 10 mg/ml		3
Cisplatin Amikacin sulfate		3578
Cisplatin : 1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
Cisplatin Amphotericin B cholesteryl sulfate complex		3578
Cisplatin Atropine sulfate		3578
Cisplatin Bleomycin sulfate		3578
Cisplatin Cefpirome sulfate		3578
Cisplatin Chloroquine sulfate		3578
Cisplatin Ephedrine sulfate		3578
Cisplatin Fluorouracil		3578
Cisplatin Fluorouracil		3474
Cisplatin : 0,5 mg/ml Fluorouracil : 10 mg/ml		413
Cisplatin : 0,2 mg/ml Fluorouracil : 1 mg/ml		413
Cisplatin : 1 mg/ml Gallium nitrate : 1 mg/ml		91

Cisplatin Gentamicin sulfate		3578
Cisplatin Isavuconazonium sulfate		3578
Cisplatin Kanamycin sulfate		3578
Cisplatin : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
Cisplatin Magnesium sulfate		3578
Cisplatin Mesna		4084
Cisplatin		3578
Cisplatin Mesna		3602
Cisplatin Morphine sulfate		3578
Cisplatin : 1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
Cisplatin : 1 mg/ml		301
Cisplatin Neostigmine methylsulfate		3578
Cisplatin Netilmicin sulfate		3578
Cisplatin Paclitaxel		3578
Cisplatin : 0.3 mg/ml Propofol		660
Cisplatin Protamine sulfate		3578
Cisplatin Salbutamol sulfate		3578
Cisplatin Sodium bicarbonate : 50 mg/ml		4084
Cisplatin Sodium bicarbonate		3578
Cisplatin Sodium thiosulfate		4084
Cisplatin Streptomycin sulfate		3578
Cisplatin Terbutaline sulfate		3578
Cisplatin : 1 mg/ml Thiotepa : 1 mg/ml		249
Cisplatin Tobramycin sulfate		3578
Cisplatin Vinblastine sulfate		3578
Cisplatin Vincristine sulfate		3578
Cisplatin Vincristine sulfate liposome		3578

Cisplatin		3578
Vindesine sulfate		
Cisplatin	NaH CO ₃	3578



Route of administration



References



















































	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53	Journal	Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57	Journal	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
91	Journal	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
147	Journal	Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV. Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container's material. Pharm World Sci 1993 ; 15: 34-36.
149	Journal	Rochard E, Barthes D, Courtois P. Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs. J Clin Pharm Ther 1992 ; 17: 315-318.
164	Journal	Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. J Clin Pharm Ther 1994 ; 19: 95-100.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
409	Journal	Cheung YW, Craddock JC, Vishnuvajjala BR, Flora KP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 1987 ; 44: 124-130.

410	Journal	Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE. Characterization of cisplatin degradation as affected by pH and light. Am J Hosp Pharm 1991 ; 48: 1500-1506.
413	Journal	Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990 ; 47: 1373-1377.
417	Journal	Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 1400-1404.
660	Journal	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
742	Journal	Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF. Stability of cisplatin in aqueous solution. Am J Hosp Pharm 1979 ; 36: 38-43.
855	Journal	Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW. Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. Cancer Chemother Pharmacol 1992 ; 29: 252-255.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Journal	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080	Journal	La Folette JM, Arbus MH, Lauper RD. Stability of cisplatin admixtures in polyvinyl chloride bags. Am J Hosp Pharm 1985 ; 42: 2652.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1729	Journal	Mittner A, Vincze Z, Jemnitz K. Stability of cisplatin containing infusion. Pharmazie 1998 ; 53: 490-492.
1950	Journal	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
3183	Journal	Sewell G Physical and chemical stability of cisplatin infusions in PVC containers. EJOP 2010 ; 4, 3: 11-13.
3474	Manufacturer	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3578	Manufacturer	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3602	Manufacturer	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3670	Journal	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
4084	Manufacturer	Cisplatine - Résumé des caractéristiques du produits Accord Health Care 2017

4137	Journal	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
------	---------	---



Dictionary

 Anticancer drug	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Length of time
 Biosimilar	 Conflicting data
 References	 Glass
 Sodium chloride 0,9%	 Protect from light
 Day	 Polyvinyl chloride
 NaCl 0,9% or Glucose 5%	 None
 Polypropylene	 Polyethylene
 Polyolefine	 Ethylene vinyl acetate
 Not specified	 Stability of mixtures
 Solvent	 Compound
 Hour	 Not specified
 Glucose 5%	 Elastomer
 Light	 Factors which affect stability
 Induces	 Degradation
 Parenteral nutrition (binary mixture)	 NaHCO ₃
 Increase	 Precipitation
 Incompatibilities	 Route of administration
 Intravenous infusion	 Continuous infusion
 Intra-arterial	 Intravesical
 Intraperitoneal	 Continuous arterial infusion
 References	 Dictionary